-
1
-
-
0037616996
-
-
National Cancer Institute Bethesda
-
L.A.G. Ries, M.P. Eisner, C.L. Kosary, B.F. Hankey, B.A. Miller, and L. Clegg SEER cancer statistics review 1975-2000 2003 National Cancer Institute Bethesda
-
(2003)
SEER Cancer Statistics Review 1975-2000
-
-
Ries, L.A.G.1
Eisner, M.P.2
Kosary, C.L.3
Hankey, B.F.4
Miller, B.A.5
Clegg, L.6
-
2
-
-
0029044886
-
Prognostic factors in patients with cervix cancer treated by radiation therapy: Results of a multiple regression analysis
-
A.W. Fyles, M. Pintilie, P. Kirkbride, W. Levin, L.A. Manchul, and G.A. Rawlings Prognostic factors in patients with cervix cancer treated by radiation therapy: results of a multiple regression analysis Radiother Oncol 35 2 May 1995 107 117
-
(1995)
Radiother Oncol
, vol.35
, Issue.2
, pp. 107-117
-
-
Fyles, A.W.1
Pintilie, M.2
Kirkbride, P.3
Levin, W.4
Manchul, L.A.5
Rawlings, G.A.6
-
3
-
-
23044495279
-
Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group study
-
H.J. Long 3rd, B.N. Bundy, E.C. Grendys Jr., J.A. Benda, D.S. McMeekin, and J. Sorosky Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study J Clin Oncol 23 21 Jul 20 2005 4626 4633
-
(2005)
J Clin Oncol
, vol.23
, Issue.21
, pp. 4626-4633
-
-
Long III, H.J.1
Bundy, B.N.2
Grendys, Jr.E.C.3
Benda, J.A.4
McMeekin, D.S.5
Sorosky, J.6
-
4
-
-
4143135504
-
Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study
-
D.H. Moore, J.A. Blessing, R.P. McQuellon, H.T. Thaler, D. Cella, and J. Benda Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study J Clin Oncol 22 15 Aug 1 2004 3113 3119
-
(2004)
J Clin Oncol
, vol.22
, Issue.15
, pp. 3113-3119
-
-
Moore, D.H.1
Blessing, J.A.2
McQuellon, R.P.3
Thaler, H.T.4
Cella, D.5
Benda, J.6
-
5
-
-
70350433286
-
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: A Gynecologic Oncology Group study
-
B.J. Monk, M.W. Sill, D.S. McMeekin, D.E. Cohn, L.M. Ramondetta, and C.H. Boardman Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study J Clin Oncol 27 28 Oct 1 2009 4649 4655
-
(2009)
J Clin Oncol
, vol.27
, Issue.28
, pp. 4649-4655
-
-
Monk, B.J.1
Sill, M.W.2
McMeekin, D.S.3
Cohn, D.E.4
Ramondetta, L.M.5
Boardman, C.H.6
-
6
-
-
47849125855
-
Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer
-
X.Y. Zhang, H.Y. Zhang, P.N. Zhang, X. Lu, and H. Sun Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer Eur J Obstet Gynecol Reprod Biol 139 2 Aug 2008 237 244
-
(2008)
Eur J Obstet Gynecol Reprod Biol
, vol.139
, Issue.2
, pp. 237-244
-
-
Zhang, X.Y.1
Zhang, H.Y.2
Zhang, P.N.3
Lu, X.4
Sun, H.5
-
7
-
-
67149137763
-
Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions
-
W. Feng, X. Duan, J. Liu, J. Xiao, and R.E. Brown Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions Int J Clin Exp Pathol 2 3 2009 249 260
-
(2009)
Int J Clin Exp Pathol
, vol.2
, Issue.3
, pp. 249-260
-
-
Feng, W.1
Duan, X.2
Liu, J.3
Xiao, J.4
Brown, R.E.5
-
8
-
-
4043171462
-
Upstream and downstream of mTOR
-
N. Hay, and N. Sonenberg Upstream and downstream of mTOR Genes Dev 18 16 Aug 15 2004 1926 1945
-
(2004)
Genes Dev
, vol.18
, Issue.16
, pp. 1926-1945
-
-
Hay, N.1
Sonenberg, N.2
-
9
-
-
4143098350
-
Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin
-
Z. Lu, X. Hu, Y. Li, L. Zheng, Y. Zhou, and H. Jiang Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin J Biol Chem 279 34 Aug 20 2004 35664 35670
-
(2004)
J Biol Chem
, vol.279
, Issue.34
, pp. 35664-35670
-
-
Lu, Z.1
Hu, X.2
Li, Y.3
Zheng, L.4
Zhou, Y.5
Jiang, H.6
-
10
-
-
0035312747
-
Regulation of translation initiation by FRAP/mTOR
-
A.C. Gingras, B. Raught, and N. Sonenberg Regulation of translation initiation by FRAP/mTOR Genes Dev 15 7 Apr 1 2001 807 826
-
(2001)
Genes Dev
, vol.15
, Issue.7
, pp. 807-826
-
-
Gingras, A.C.1
Raught, B.2
Sonenberg, N.3
-
11
-
-
84860363833
-
MTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas
-
A.A. Molinolo, C. Marsh, M. El Dinali, N. Gangane, K. Jennison, and S. Hewitt mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas Clin Cancer Res 18 9 May 1 2012 2558 2568
-
(2012)
Clin Cancer Res
, vol.18
, Issue.9
, pp. 2558-2568
-
-
Molinolo, A.A.1
Marsh, C.2
El Dinali, M.3
Gangane, N.4
Jennison, K.5
Hewitt, S.6
-
12
-
-
34249779568
-
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
-
G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, and A. Kapoor Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 22 May 31 2007 2271 2281
-
(2007)
N Engl J Med
, vol.356
, Issue.22
, pp. 2271-2281
-
-
Hudes, G.1
Carducci, M.2
Tomczak, P.3
Dutcher, J.4
Figlin, R.5
Kapoor, A.6
-
13
-
-
48649107474
-
Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial
-
R.J. Motzer, B. Escudier, S. Oudard, T.E. Hutson, C. Porta, and S. Bracarda Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 9637 Aug 9 2008 449 456
-
(2008)
Lancet
, vol.372
, Issue.9637
, pp. 449-456
-
-
Motzer, R.J.1
Escudier, B.2
Oudard, S.3
Hutson, T.E.4
Porta, C.5
Bracarda, S.6
-
14
-
-
68949102180
-
Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma
-
G. Hess, R. Herbrecht, J. Romaguera, G. Verhoef, M. Crump, and C. Gisselbrecht Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma J Clin Oncol 27 23 Aug 10 2009 3822 3829
-
(2009)
J Clin Oncol
, vol.27
, Issue.23
, pp. 3822-3829
-
-
Hess, G.1
Herbrecht, R.2
Romaguera, J.3
Verhoef, G.4
Crump, M.5
Gisselbrecht, C.6
-
15
-
-
79851500081
-
Everolimus for advanced pancreatic neuroendocrine tumors
-
J.C. Yao, M.H. Shah, T. Ito, C.L. Bohas, E.M. Wolin, and E. Van Cutsem Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 6 Feb 10 2011 514 523
-
(2011)
N Engl J Med
, vol.364
, Issue.6
, pp. 514-523
-
-
Yao, J.C.1
Shah, M.H.2
Ito, T.3
Bohas, C.L.4
Wolin, E.M.5
Van Cutsem, E.6
-
16
-
-
57849117384
-
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
-
E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, and R. Ford New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2 Jan 2009 228 247
-
(2009)
Eur J Cancer
, vol.45
, Issue.2
, pp. 228-247
-
-
Eisenhauer, E.A.1
Therasse, P.2
Bogaerts, J.3
Schwartz, L.H.4
Sargent, D.5
Ford, R.6
-
17
-
-
0024536437
-
Optimal two-stage designs for phase II clinical trials
-
R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1 Mar 1989 1 10
-
(1989)
Control Clin Trials
, vol.10
, Issue.1
, pp. 1-10
-
-
Simon, R.1
-
18
-
-
33748288069
-
Metaphase and array comparative genomic hybridization: Unique copy number changes and gene amplification of medulloblastomas in South America
-
M. Yoshimoto, J. Bayani, P.A. Nuin, N.S. Silva, S. Cavalheiro, and J.N. Stavale Metaphase and array comparative genomic hybridization: unique copy number changes and gene amplification of medulloblastomas in South America Cancer Genet Cytogenet 170 1 Oct 1 2006 40 47
-
(2006)
Cancer Genet Cytogenet
, vol.170
, Issue.1
, pp. 40-47
-
-
Yoshimoto, M.1
Bayani, J.2
Nuin, P.A.3
Silva, N.S.4
Cavalheiro, S.5
Stavale, J.N.6
-
19
-
-
64549158092
-
Overexpression of PIK3CA is associated with lymph node metastasis in esophageal squamous cell carcinoma
-
I. Akagi, M. Miyashita, H. Makino, T. Nomura, N. Hagiwara, and K. Takahashi Overexpression of PIK3CA is associated with lymph node metastasis in esophageal squamous cell carcinoma Int J Oncol 34 3 Mar 2009 767 775
-
(2009)
Int J Oncol
, vol.34
, Issue.3
, pp. 767-775
-
-
Akagi, I.1
Miyashita, M.2
Makino, H.3
Nomura, T.4
Hagiwara, N.5
Takahashi, K.6
-
20
-
-
34548299547
-
FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome
-
M. Yoshimoto, I.W. Cunha, R.A. Coudry, F.P. Fonseca, C.H. Torres, and F.A. Soares FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome Br J Cancer 97 5 Sep 3 2007 678 685
-
(2007)
Br J Cancer
, vol.97
, Issue.5
, pp. 678-685
-
-
Yoshimoto, M.1
Cunha, I.W.2
Coudry, R.A.3
Fonseca, F.P.4
Torres, C.H.5
Soares, F.A.6
-
21
-
-
61549141361
-
Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study
-
B.J. Monk, M.W. Sill, R.A. Burger, H.J. Gray, T.E. Buekers, and L.D. Roman Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study J Clin Oncol 27 7 Mar 1 2009 1069 1074
-
(2009)
J Clin Oncol
, vol.27
, Issue.7
, pp. 1069-1074
-
-
Monk, B.J.1
Sill, M.W.2
Burger, R.A.3
Gray, H.J.4
Buekers, T.E.5
Roman, L.D.6
-
22
-
-
84861690519
-
Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer
-
I. Diaz-Padilla, I. Duran, B.A. Clarke, and A.M. Oza Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer Cancer Treat Rev 38 6 Oct 2012 767 775
-
(2012)
Cancer Treat Rev
, vol.38
, Issue.6
, pp. 767-775
-
-
Diaz-Padilla, I.1
Duran, I.2
Clarke, B.A.3
Oza, A.M.4
-
23
-
-
77955874058
-
Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer
-
B.J. Monk, L. Mas Lopez, J.J. Zarba, A. Oaknin, C. Tarpin, and W. Termrungruanglert Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer J Clin Oncol 28 22 Aug 1 2010 3562 3569
-
(2010)
J Clin Oncol
, vol.28
, Issue.22
, pp. 3562-3569
-
-
Monk, B.J.1
Mas Lopez, L.2
Zarba, J.J.3
Oaknin, A.4
Tarpin, C.5
Termrungruanglert, W.6
-
24
-
-
84864410952
-
Changing demographics of cervical cancer in the United States (1973-2008)
-
K.K. Ward, N.R. Shah, C.C. Saenz, M.T. McHale, E.A. Alvarez, and S.C. Plaxe Changing demographics of cervical cancer in the United States (1973-2008) Gynecol Oncol 126 3 Sep 2012 330 333
-
(2012)
Gynecol Oncol
, vol.126
, Issue.3
, pp. 330-333
-
-
Ward, K.K.1
Shah, N.R.2
Saenz, C.C.3
McHale, M.T.4
Alvarez, E.A.5
Plaxe, S.C.6
-
25
-
-
70749142744
-
Adenocarcinoma: A unique cervical cancer
-
L.T. Gien, M.C. Beauchemin, and G. Thomas Adenocarcinoma: a unique cervical cancer Gynecol Oncol 116 1 Jan 2010 140 146
-
(2010)
Gynecol Oncol
, vol.116
, Issue.1
, pp. 140-146
-
-
Gien, L.T.1
Beauchemin, M.C.2
Thomas, G.3
-
26
-
-
84863393080
-
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing
-
M. Gerlinger, A.J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, and E. Gronroos Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 366 10 Mar 8 2012 883 892
-
(2012)
N Engl J Med
, vol.366
, Issue.10
, pp. 883-892
-
-
Gerlinger, M.1
Rowan, A.J.2
Horswell, S.3
Larkin, J.4
Endesfelder, D.5
Gronroos, E.6
-
27
-
-
84880261973
-
Intratumoral heterogeneity in high-grade serous cancers: Defining evolution of the somatic mutational landscape across spatially and temporally selected samples
-
J.N. McAlpine, A. Bashashati, G. Ha, J. Rosner, J. Ding, and K. Shumansky Intratumoral heterogeneity in high-grade serous cancers: defining evolution of the somatic mutational landscape across spatially and temporally selected samples IGCS 2012:Plenary Session 2012
-
(2012)
IGCS 2012:Plenary Session
-
-
McAlpine, J.N.1
Bashashati, A.2
Ha, G.3
Rosner, J.4
Ding, J.5
Shumansky, K.6
-
28
-
-
70349969478
-
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution
-
S.P. Shah, R.D. Morin, J. Khattra, L. Prentice, T. Pugh, and A. Burleigh Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution Nature 461 7265 Oct 8 2009 809 813
-
(2009)
Nature
, vol.461
, Issue.7265
, pp. 809-813
-
-
Shah, S.P.1
Morin, R.D.2
Khattra, J.3
Prentice, L.4
Pugh, T.5
Burleigh, A.6
|